Cargando…

High frequency of brain metastases after adjuvant therapy for high‐risk melanoma

The incidence of CNS progression in patients with high‐risk regional melanoma (stages IIIAN2a‐IIIC) is not well characterized. Data from the S0008 trial provided an opportunity to examine the role of CNS progression in treatment failure and survival. All patients were surgically staged. Following wi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Samlowski, Wolfram E., Moon, James, Witter, Merle, Atkins, Michael B., Kirkwood, John M., Othus, Megan, Ribas, Antoni, Sondak, Vernon K., Flaherty, Lawrence E.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2017
Materias:	Clinical Cancer Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5673911/ https://www.ncbi.nlm.nih.gov/pubmed/28994212 http://dx.doi.org/10.1002/cam4.1223

Ejemplares similares

Granulomatous and Sarcoid-like Immune-Related Adverse Events following CTLA4 and PD1 Blockade Adjuvant Therapy of Melanoma: A Combined Analysis of ECOG-ACRIN E1609 and SWOG S1404 Phase III Trials and a Literature Review
por: Eljilany, Islam, et al.
Publicado: (2023)

Phase II Trial of Sorafenib in Combination with Carboplatin and Paclitaxel in Patients with Metastatic Uveal Melanoma: SWOG S0512
por: Bhatia, Shailender, et al.
Publicado: (2012)

Management of Melanoma Brain Metastases in the Era of Targeted Therapy
por: Shapiro, Daniela Gonsalves, et al.
Publicado: (2011)

Immune adverse events (irAEs) with adjuvant ipilimumab in melanoma, use of immunosuppressants and association with outcome: ECOG-ACRIN E1609 study analysis
por: Tarhini, Ahmad A, et al.
Publicado: (2021)

Correlation of molecular human leukocyte antigen typing and outcome in high-risk melanoma patients receiving adjuvant interferon
por: Gogas, Helen, et al.
Publicado: (2010)

Improved prognosis and evidence of enhanced immunogenicity in tumor and circulation of high-risk melanoma patients with unknown primary
por: Tarhini, Ahmad A, et al.
Publicado: (2022)

Nonsentinel Node Metastases in Melanoma: Do They Reflect the Biology of the Tumor, the Lymph Node or the Surgeon?: Editorial to Accompany Ghaferi et al., ASO-2009-03-0312.R1
por: Sondak, Vernon K.
Publicado: (2009)

Higher than reported adolescent and young adult clinical trial enrollment during the “Golden Age” of melanoma clinical trials
por: Sreeraman Kumar, Radhika, et al.
Publicado: (2018)

Cost‐effectiveness of ipilimumab versus high‐dose interferon as an adjuvant therapy in resected high‐risk melanoma
por: Salans, Mia, et al.
Publicado: (2021)

Molecular profiling of melanoma brain metastases compared to primary cutaneous melanoma and to extracranial metastases
por: In, Gino K., et al.
Publicado: (2020)

Real‐World nivolumab dosing patterns and safety outcomes in patients receiving adjuvant therapy for melanoma
por: Samlowski, Wolfram, et al.
Publicado: (2022)

Retreatment of Patients With Metastatic Cutaneous Melanoma Who Relapse After Elective Checkpoint Inhibitor Discontinuation After a Complete Remission
por: Sadrolashrafi, Kaviyon, et al.
Publicado: (2023)

Cautious addition of targeted therapy to PD-1 inhibitors after initial progression of BRAF mutant metastatic melanoma on checkpoint inhibitor therapy
por: Samlowski, Wolfram, et al.
Publicado: (2021)

Adjuvant interferon in the treatment of melanoma
por: Kirkwood, J M
Publicado: (2000)

Adjuvant Therapy: Melanoma
por: Davar, Diwakar, et al.
Publicado: (2011)

Who Is to Blame for False-Negative Sentinel Node Biopsies in Melanoma?
por: Sondak, Vernon K., et al.
Publicado: (2009)

Enhanced immune activation within the tumor microenvironment and circulation of female high-risk melanoma patients and improved survival with adjuvant CTLA4 blockade compared to males
por: Saad, Mariam, et al.
Publicado: (2022)

Targeting hyperactivation of the AKT survival pathway to overcome therapy resistance of melanoma brain metastases
por: Niessner, Heike, et al.
Publicado: (2013)

Survival of melanoma patients with brain metastases treated with ipilimumab and stereotactic radiosurgery
por: Tazi, Karim, et al.
Publicado: (2015)

Ipilimumab and radiation therapy for melanoma brain metastases
por: Silk, Ann W, et al.
Publicado: (2013)

Pharmacokinetic/pharmacodynamic analysis of adjuvant pegylated interferon α-2b in patients with resected high-risk melanoma
por: Daud, A. I., et al.
Publicado: (2010)

Metachronous Peritoneal Metastases After Adjuvant Chemotherapy are Associated with Poor Outcome After Cytoreduction and HIPEC
por: Sluiter, Nina R., et al.
Publicado: (2018)

High frequency of lobular breast cancer in distant metastases to the orbit
por: Raap, Mieke, et al.
Publicado: (2015)

Efficacy and toxicity of adjuvant radiotherapy in recurrent melanoma after adjuvant immunotherapy
por: Bhave, Prachi, et al.
Publicado: (2023)

Phase II clinical and immune correlate study of adjuvant nivolumab plus ipilimumab for high-risk resected melanoma
por: Khushalani, Nikhil I, et al.
Publicado: (2022)

Outcome of Elective Checkpoint Inhibitor Discontinuation in Patients with Metastatic Melanoma Who Achieved a Complete Remission: Real-World Data
por: Perez, Leanne, et al.
Publicado: (2022)

Lack of Influence of Non-Overlapping Mutations in BRAF, NRAS, or NF1 on 12-Month Best Objective Response and Long-Term Survival after Checkpoint Inhibitor-Based Treatment for Metastatic Melanoma
por: Panning, Alyssa, et al.
Publicado: (2023)

Comprehensive analysis of cutaneous and uveal melanoma liver metastases
por: Hoefsmit, Esmee P, et al.
Publicado: (2020)

Large cell non-Hodgkin's lymphoma masquerading as renal carcinoma with inferior vena cava thrombosis: a case report
por: Samlowski, Erika E, et al.
Publicado: (2011)

Adjuvant therapy for high-risk melanoma
por: Eggermont, Alexander M.M.
Publicado: (2013)

Predictive value of a nomogram for melanomas with brain metastases at initial diagnosis
por: Liu, Hong, et al.
Publicado: (2019)

Recent survival trends in diffuse large B‐cell lymphoma––Have we made any progress beyond rituximab?
por: Epperla, Narendranath, et al.
Publicado: (2020)

Adjuvant therapy of melanoma with interferon: lessons of the past decade
por: Ascierto, Paolo A, et al.
Publicado: (2008)

Focal radiation necrosis of the brain in patients with melanoma brain metastases treated with pembrolizumab
por: Du Four, Stephanie, et al.
Publicado: (2018)

Real world outcomes of combination and timing of immunotherapy with radiotherapy for melanoma with brain metastases
por: Moyers, Justin T., et al.
Publicado: (2021)

Survival outcomes in an older US population with advanced melanoma and central nervous system metastases: SEER‐Medicare analysis
por: Sadetsky, Natalia, et al.
Publicado: (2020)

Adjuvant Ipilimumab in High-Risk Uveal Melanoma
por: Fountain, Eric, et al.
Publicado: (2019)

Baseline Serum Autoantibody Signatures Predict Recurrence and Toxicity in Melanoma Patients Receiving Adjuvant Immune Checkpoint Blockade
por: Johannet, Paul, et al.
Publicado: (2022)

Adjuvant radiotherapy and outcomes of presumed hemorrhagic melanoma brain metastases without malignant cells
por: Xia, Yuanxuan, et al.
Publicado: (2018)

Phase II clinical trial evaluating docetaxel, vinorelbine and GM-CSF in stage IV melanoma
por: Eroglu, Zeynep, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_iiv02h9qg5hh6el45nm603uqfr